Transgene Biotek Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Public

  • Stock Symbol
  • 526139

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $0.05
  • (As of Tuesday Closing)

Transgene Biotek General Information

Description

Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.

Contact Information

Website
www.transgenebiotek.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 69 & 70 IDA Bollaram
  • Sangareddy, Telangana 502325
  • India
+91 084582
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Stock Exchange
BOM
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 69 & 70 IDA Bollaram
  • Sangareddy, Telangana 502325
  • India
+91 084582

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Transgene Biotek Stock Performance

As of 20-May-2025, Transgene Biotek’s stock price is $0.05. Its current market cap is $3.64M with 75.8M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.05 $0.05 $0.04 - $0.13 $3.64M 75.8M 31.1K

Transgene Biotek Financials Summary

As of 31-Mar-2025, Transgene Biotek has a trailing 12-month revenue of $30.8K.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023
EV 4,633 4,633 9,025 3,837
Revenue 31 31 28 7
EBITDA (40) (40) (52) (54)
Net Income (80) (80) (79) (748)
Total Assets 16,845 16,845 17,067 17,339
Total Debt 1,697 1,697 1,679 1,597
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Transgene Biotek Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Transgene Biotek‘s full profile, request access.

Request a free trial

Transgene Biotek Patents

  • 14

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • Pending

  • Expiring in next 12 mo

Transgene Biotek Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2014282802-A1 Pharmaceutical formulations and methods for oral delivery of biologically active ingredient Active 18-Jun-2013
AU-2014282802-B2 Pharmaceutical formulations and methods for oral delivery of biologically active ingredient Active 18-Jun-2013
EP-3010534-B1 Pharmaceutical formulations and methods for oral delivery of biologically active ingredient Active 18-Jun-2013
EP-3010534-A2 Pharmaceutical formulations and methods for oral delivery of biologically active ingredient Active 18-Jun-2013
EP-3010534-A4 Pharmaceutical formulations and methods for oral delivery of biologically active ingredient Active 18-Jun-2013 A61K38/28
To view Transgene Biotek’s complete patent history, request access »

Transgene Biotek Investments & Acquisitions (4)

Transgene Biotek’s most recent deal was a Merger/Acquisition with Indicia Production (Immuno Monitoring Business). The deal was made on 31-Jul-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Indicia Production (Immuno Monitoring Business) 31-Jul-2013 Merger/Acquisition Other Healthcare Services
Jennerex Biotherapeutics 23-May-2013 Later Stage VC Drug Discovery
ElsaLys Biotech 17-May-2013 Early Stage VC Biotechnology
Marillion Pharmaceuticals 05-Aug-2010 Merger/Acquisition Drug Discovery
To view Transgene Biotek’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Transgene Biotek Exits (2)

Transgene Biotek’s most recent exit was on 23-May-2013 from Jennerex Biotherapeutics. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Jennerex Biotherapeutics 23-May-2013 Completed
ElsaLys Biotech 17-May-2013 Early Stage VC Completed
  • 2 buyers
To view Transgene Biotek’s complete exits history, request access »

Transgene Biotek Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Marillion Pharmaceuticals Malvern, PA 2005

Transgene Biotek FAQs

  • When was Transgene Biotek founded?

    Transgene Biotek was founded in 1990.

  • Where is Transgene Biotek headquartered?

    Transgene Biotek is headquartered in Sangareddy, India.

  • What industry is Transgene Biotek in?

    Transgene Biotek’s primary industry is Biotechnology.

  • Is Transgene Biotek a private or public company?

    Transgene Biotek is a Public company.

  • What is Transgene Biotek’s stock symbol?

    The ticker symbol for Transgene Biotek is 526139.

  • What is the current stock price of Transgene Biotek?

    As of 20-May-2025 the stock price of Transgene Biotek is $0.05.

  • What is the current market cap of Transgene Biotek?

    The current market capitalization of Transgene Biotek is $3.64M.

  • What is Transgene Biotek’s current revenue?

    The trailing twelve month revenue for Transgene Biotek is $30.8K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »